Navigation Links
CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement

Seeks Exclusion Order Barring Importation of CryoCath's Cryoablation System

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it has filed a formal complaint with the United States International Trade Commission (ITC) alleging that CryoCath Technologies Inc. has engaged in unfair trade practices by infringing on several CryoCor patents with its cryoablation system. CryoCor is requesting that the ITC initiate an investigation and issue an exclusion order to bar the importation into the United States of infringing CryoCath cryoablation products.

CryoCor's complaint covers three patents exclusively licensed to CryoCor in certain fields of use related to its Cardiac Cryoablation System, including patents covering pre-cooling technologies that CryoCor considers important to CryoCath's cryoablation system. This action is independent of a patent interference that has been declared by the United States Patent and Trademark Office between CryoCor and CryoCath, where CryoCor has been declared the senior party.

If the ITC accepts the complaint, it will institute a formal Section 337 investigation within 30 days. Section 337 investigations are completed on a fast track, typically within 15 months of the submission of the complaint. If the ITC determines that CryoCath's cryoablation system infringes on CryoCor's licensed patents and that CryoCath's products are being imported into the United States, the ITC may order that CryoCath's cryoablation system, and associated catheters and parts, be completely excluded from importation into the U.S. market for the life of the patents. ITC exclusion orders are enforced by the U.S. Customs and Border Protection.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "Our request for this investigation further reinforces our strategy to protect our intellectual property rights. Importantly, an ITC investigation has a fast timeline for completion, usually just over one year. If we prevail, the ITC may issue a ban on importation of CryoCath's cryoablation system into the United States. We expect to hear from the ITC within 30 days and will provide an update upon their response. We are confident in the strength of our patent portfolio and believe that we have a solid position as a technological leader in cardiac cryoablation."

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to whether the ITC will accept CryoCor's complaint, the possible remedies that may be imposed against CryoCath by the ITC, the merits of CryoCor's positions in the ITC proceedings with CryoCath, the possible outcome of those proceedings, and the value of pre-cooling technology in a cryoablation system, and specifically, CryoCath's cryoablation system, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.

CryoCor, Inc. The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)

Chief Financial Officer (646) 536-7030 / 7020

(858) 909-2200

Jason Rando (media)

(646) 536-7025

SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. United States Patent Office Grants CryoCors Request for Patent Interference
2. CryoCor Files Patent Infringement Lawsuits Against CryoCath
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. CryoCor to Present at CIBC World Markets 18th Annual Healthcare Conference
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. Sinovac Requests Extension for Annual Shareholders Meeting
7. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
8. International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy
9. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
10. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
11. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... 24, 2015 HemoShear Therapeutics, LLC, a ... for metabolic disorders, announced today the appointment of ... of Directors (BOD). Mr. Watkins is the former ... Sciences (HGS), and also served as the chairman ... Powers , Chairman and CEO of HemoShear Therapeutics. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 According to ... than in 2005. This is something that many doctors, scientists, ... time. One questions remains: with fewer PSA tests being done, ... ? Dr. David Samadi, "Despite the ... the disease remains the second leading cancer cause of death ...
(Date:11/23/2015)... ... November 23, 2015 , ... ... development of its Nexera UC Unified Chromatography system. The award from R&D magazine ... new products of the year in the analytical and testing category. R&D Magazine ...
Breaking Biology Technology:
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... 29, 2015  Connected health pioneer, Joseph C. ... of technology-enabled health and wellness, and the business opportunities ... The Internet of Healthy Things . Long ... even existed, Dr. Kvedar, vice president, Connected Health, Partners ... delivery, moving care from the hospital or doctor,s office ...
Breaking Biology News(10 mins):